GenSight Biologics S.A.
GSGTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | -$0 | $0 | -$0 |
| % Growth | 121.1% | -113.2% | 710.6% | – |
| Gross Profit | $0 | -$0 | $0 | -$0 |
| % Margin | 100% | 100% | 100% | 849.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -12,211.8% | 1,766.2% | -424.9% | 4,065.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -14,514.6% | 3,575.9% | -338.4% | 5,038.2% |
| EPS Diluted | -0.054 | -0.099 | -0.071 | -0.28 |
| % Growth | 45.4% | -40.8% | 74.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |